Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Sotio Biotech Inc.
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
VM Oncology, LLC
Incyte Corporation
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
A2 Biotherapeutics Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited